Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
ClinicoEconomics and outcomes research : CEOR（2023）
摘要
Empagliflozin is a cost-effective treatment for patients with HF in the Finnish health care setting.
更多查看译文
关键词
cost-utility analysis,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,sodium-glucose cotransporter 2 inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要